← Back to Pipeline Dashboard Open Source Medicine Foundation

Recombinant Human Papillomavirus Bivalent Vaccine

Phase 3 Clinical Trial

Developer: National Cancer Institute (NCI)  |  Target Disease: HPV

Category Resource

Explore licensed vaccines, adverse event reporting data, and history for this disease.

View HPV Vaccine Guide →
Development Phase Phase 3 Clinical Trial Primary Status
Platform Technology Protein / subunit Biologic Architecture
Target Indication HPV Pathogen / Antigen
Last Verified 2026-07-10 Tier 1 Multi-Source Checked

Multi-Jurisdiction Regulatory Status

Official licensing, rolling submissions, or authorization status tracked across major health authorities.

Regulatory Authority Status & Details
US FDA Not Filed / Pre-submission
EMA (Europe) Not Filed / Pre-submission
Health Canada Not Filed / Pre-submission
TGA (Australia) Not Filed / Pre-submission

Scientific Profile & Documentation

Platform Architecture
Protein / subunit
Lead Developer
National Cancer Institute (NCI)
Next Expected Milestone
Primary completion (most advanced trial): 2025-08-21 (registry estimate)
Analyst & Development Notes
Auto-grouped from 2 ClinicalTrials.gov record(s) sharing intervention/sponsor. Phases and timelines are registry fields and may lag company disclosures.
Primary Source Documentation
ClinicalTrials.gov NCT03180034 →
Additional Sources & Literature

Registered Clinical Trials & Studies

Direct registry links to active, completed, or pivotal registration studies across phases.

NCT03180034 Phase 3 Clinical Trial

Comparing One or Two Doses of the Human Papillomavirus Vaccine for the Prevention of Human Papillomavirus Infection, ESC

Status: Active / Ongoing • Expected Readout: 2025-08-21
NCT05237947 Phase 3 Clinical Trial

Single-Dose HPV Vaccination for the Prevention of Cervical Cancer in Young Adult Women in Costa Rica, The PRISMA ESCUDDO

Status: Active / Ongoing • Expected Readout: 2026-08-31

Milestone Overview

  • Stage Verification
    Phase 3 Clinical Trial confirmed as of 2026-07-10.
  • Target Milestone
    Primary completion (most advanced trial): 2025-08-21 (registry estimate)

Vaccine Data Navigator Candidate Profile Registry:

This candidate profile is indexed across all clinical development levels (Preclinical through Phase 1–3, Regulatory Filing, and Licensure) from primary registry databases (ClinicalTrials.gov, WHO ICTRP, FDA CBER, EMA, Health Canada, TGA Australia). Data are updated continuously to track global biologic and vaccine pipelines.